Inclusion criteria  Radiologically strong suspicion of pCCA Tumor can involve intrahepatic portal vein without thrombosis of extrahepatic portal vein Tumor can involve hepatic artery distal to gastroduodenal artery or involve replaced hepatic artery First time pCCA Disease deemed not eligible for liver resection based on tumor location or underlying liver dysfunction No extrahepatic disease, or lymph node involvement detected on imaging No signs of extrahepatic metastatic disease according to PET-CT scan No signs of extrahepatic metastatic disease according to CT or MR (chest/abdomen/pelvis) scan within 4 weeks prior to the faculty meeting at the transplant unit At least 18 years of age Good performance status, Eastern Cooperative Oncology Group (ECOG) score: 0 or 1 Satisfactory blood tests Hb >10g/dl, neutrophiles >1.0 (after any G-CSF), TRC >50, Bilirubin<3 x upper normal level, ASAT, ALAT<5 x upper normal level, Creatinine <1.5 x upper normal level. Albumin above lower normal level, Normal IgG4 levels Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to GCP, and national/local regulations Received chemotherapy for at least 6 months with at least 10% response according ti RECIST criteria and with no progression of disease at time of Lt At least 10 months from diagnosis Patient must be accepted for transplantation before progressive disease Twelve months or more time span from the diagnosis of pCCA and date of being listed for liver transplantation  Exclusion criteria  Tumor involving common hepatic artery, celiac trunck or superior mesenteric artery the tumor Tumor involving main portal vein Tumor involving inferior vena cava Perforation of the visceral peritoneum Weight loss >15% the last 6 months Patient BMI > 30 Other malignancies, except curatively treated more than 5 years ago without relapse Known history of human immunodeficiency virus (HIV) infection Prior history of solid organ or bone marrow transplantation Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results Known hypersensitivity to rapamycin Prior extrahepatic metastatic disease Women who are pregnant or breast feeding Any reason why, in the opinion of the investigator, the patient should not participate